---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000043"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:38:23.727177+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Positive Cohort B ASCEND data: 6M PFS 60.8% (certepetide) vs 25% (placebo)

## Summary
- Cohort B: median PFS 7.5 months (certepetide) vs 4.7 months (placebo); ORR 45.2% vs 19%.
- Median OS 10.32 months (certepetide) vs 9.23 months (placebo); safety profile attractive.
- Cohort B regimen (two doses of certepetide) showed clinically meaningful improvement over Cohort A.
- Full data from both cohorts expected later 2025; presented at ESMO GI on 2 July 2025.

## SEC filing metadata
- accession: 0000320017-25-000043
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000043/0000320017-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000043/clbs-20250626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000043
- JSON: https://secwatch.observer/filing/0000320017-25-000043.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.